Home

Stephen C. Glover

CIK 1304406 · Chief Executive Officer · last filed 2026-06-03

Stephen C. Glover is a Chief Executive Officer who has filed 20 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ONCY, was dated Jun 3, 2026. Across all open-market trades the lifetime net is +$137.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.20M

Companies

6

Total Filings

20

Lifetime Open-Market Net

$137.9K

Filer Profile

Reported Address
108 DOCKSIDE CIRCLE
WESTON, FL 33327
Formerly Known As
Glover Steve C (2004–2022)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ONCY Director — $0.75 — $0 1 2026-06-03
PDSB Director 78,851 $0.29 $23.3K $75.0K 10 2026-03-03
ZyVersa Therapeutics, Inc. (ZVSA) Delisted Chief Executive Officer — $0.20 — $0 2 2025-07-15
Ambrx Biopharma, Inc. (AMAM) Delisted Director 85,000 $28.00 $2.38M $0 3 2024-03-07
ZyVersa Therapeutics, Inc. (ZVSAW) Delisted Chief Executive Officer 492,756 — — $0 1 2022-12-14
INSM President Follow-on Biologics 47,716 $129.41 $6.17M $62.9K 3 2009-04-02

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-03 ONCY Grant (A) — $0 EDGAR
2026-03-03 PDSB Grant (A) — $0 EDGAR
2025-07-15 ZyVersa Therapeutics, Inc. (ZVSA) Delisted Grant (A) — $0 EDGAR
2025-06-11 PDSB Grant (A) — $0 EDGAR
2025-03-03 PDSB Buy (P) +15,061 $25.0K EDGAR
2024-07-18 ZyVersa Therapeutics, Inc. (ZVSA) Delisted Grant (A) — $0 EDGAR
2024-06-25 PDSB Grant (A) — $0 EDGAR
2024-03-07 Ambrx Biopharma, Inc. (AMAM) Delisted Disp (D) — $0 EDGAR
2023-07-17 PDSB Grant (A) — $0 EDGAR
2023-06-09 Ambrx Biopharma, Inc. (AMAM) Delisted Grant (A) +85,000 $0 EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.